CuraGen Corp. and TopoTarget A/S have started a Phase I/II clinical trial evaluating the safety and potential efficacy of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of inoperable hepatocellular (liver) cancer. This trial is being sponsored by the National Cancer Institute (NCI) under a Clinical Trials Agreement with CuraGen for PXD101. The trial is an open-label study being led by Dr. Winnie Yeo at the Department of Clinical Oncology, Chinese University o...